Skip to cookie consent Skip to main content

Mass General Brigham

Hospital Research Institutes

As a world-recognized leader in research, Mass General Brigham is home to one of the largest hospital system-based research enterprises in the U.S. 

female researcher looking in microscope in lab

Mass General Brigham’s location in the Massachusetts biotech and academic medical communities creates enhanced collaborations with partners from academia, industry, and venture capital to help stimulate the development of our discoveries into lifesaving therapies for our patients.

The greatest minds at our hospitals have a history of pushing the boundaries of medicine and leading innovative science for over 200 years. We have a legacy of medical achievement, with numerous medical firsts and 13 Nobel Laureates.

Our hospital-based medical research institutes

$2 billion in research activities

World-class innovators find the therapies and technologies of tomorrow

  • A team of researchers at Massachusetts Eye and Ear and Harvard Medical School (HMS) have successfully restored vision in elderly mice by turning back the clock on their aged nerve cells in the retina to recapture their youthful function.

  • The biggest benefit of tendoscopy over traditional, open-incision surgery is that it requires less soft tissue dissection. By not disrupting the soft tissue, surgeons can see tendons in their native environment and observe how they move and glide as part of the surgery. 

  • A multidisciplinary team of cardiac specialists at Massachusetts General Hospital's Lead Management Program are making clinical and research advances to optimize patient outcomes in patients with cardiac implantable electronic devices that must be removed or replaced.

  • Early in the pandemic, Dr. Edlow and her colleagues established the Mass General Brigham COVID-19 in Pregnancy Biorepository to better understand interactions between pregnancy and SARS-CoV-2, including pregnancy-specific immune response to COVID-19.

  • A team of investigators from Brigham and Women’s Hospital and MIT is using the power of nanotechnology to develop an entirely new approach for boosting the immune response to cancer. 

  • Early reports of anaphylaxis—a life-threatening whole-body allergic reaction—associated with the first mRNA-based COVID-19 vaccines caused widespread concern about the safety of the vaccines. Now, a team of researchers at Mass General Brigham reports that the risk of anaphylaxis with the vaccines, although slightly higher than estimated by the CDC, is low.